ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/melanoma/adjuvant-neoadjuvant
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Melanoma and skin / Melanoma - Adjuvant/neoadjuvant
9
trial(s) found.
NCT06190951
Curative
Phase 2 / Phase 3
Recruiting
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma (
R3767-ONC-2208
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05608291
Curative
Phase 3
Recruiting
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma (
R3767-ONC-2055
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT05418972
Curative
Phase 2
Recruiting
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (
Neo-ReNi-II
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT03897881
Curative
Phase 2
Recruiting
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942) (
mRNA-4157-P201
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6150 - Murdoch - Affinity Clinical Research
NCT05933577
Curative
Phase 3
Active not recruiting
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001) (
V940-001
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05665595
Curative
Phase 3
Active not recruiting
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010) (
7684A-010
)
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Tasman Oncology
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
TAS
7000 - Hobart - ICON Cancer Care Hobart
NZ
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT05545969
Curative
Phase 2
Withdrawn
A Multicentre, Open Label, Phase II Study to Determine the Response to Neoadjuvant Pembrolizumab and Lenvatinib Followed by Adjuvant Treatment With Pembrolizumab and Lenvatinib in Mucosal Melanoma (
Neo-PeLeMM
)
VEGF inhibitor
anti-PD-1 monoclonal antibody
Mucosal melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT05297565
Curative
Phase 3
Completed
A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Subcutaneous (Nivo SC) Versus Intravenous (Nivo IV) Administration in Participants With Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma Following Complete Resection (
CheckMate-6GE
)
anti-PD-1 monoclonal antibody
Melanoma
NSW
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
VIC
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
NCT05270044
Curative
Phase 3
Active not recruiting
Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group (
COLUMBUS-AD
)
BRAF V600 inhibitor
MEK inhibitor
placebo
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3181 - Prahran - The Alfred Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Hollywood Private Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Active not recruiting (3)
Withdrawn (1)
Completed (1)
Recruitment Country and State
NSW (9)
VIC (6)
WA (5)
SA (4)
QLD (4)
NZ (2)
TAS (1)
Phase
Phase 2 (3)
Phase 2 / Phase 3 (1)
Phase 3 (5)
Trial Type
Curative (9)
Cancer Therapy Class
PD-1
89%
PD-1/PD-L1
89%
LAG3
33%
TIGIT
11%
VEGF
11%
BRAF
11%
BRAF V600
11%
MEK
11%
RAF
11%
Facility
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (8)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
6009 - Nedlands - One Clinical Research (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
3004 - Melbourne, Southbank - Alfred Health (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (2)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
6150 - Murdoch - Affinity Clinical Research (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
4215 - Southport - Tasman Oncology (1)
4870 - Cairns - Cairns Base Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2500 - Wollongong - Wollongong Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3181 - Prahran - The Alfred Hospital (1)
6009 - Nedlands - Hollywood Private Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
Cancer Type
Cancer
Melanoma
Solid tumour
Mucosal melanoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy